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Papillary thyroid carcinoma (PTC), sometimes found as a familial
disease (Fisher et al, 1989; Lote et al, 1980; Ron et al, 1991;
Gorson, 1992), may be occasionally associated with Graves’
disease (Soh and Parc, 1993), lymphocytic thyroiditis (McKee 
et al, 1993; Okayasu et al, 1995) or Hashimoto’s thyroiditis
(Walker et Paloyan, 1990; Sclafani et al, 1993; Reda et al, 1997;
Wirtschafter et al, 1997). It has been suggested that lymphocytic
thyroiditis may be a predisposing pathology for PTC, perhaps
through the activation of the ret proto-oncogene by a mechanism
of chromosomal rearrangement (Ishizaka et al, 1991; Wirtschafter
et al, 1997). However causative relations between the 2 noso-
logical entities are still uncertain. 
The  ret proto-oncogene, located on chromosome 10q 11.2,
encodes for a protein structurally related to transmembrane recep-
tors with a tyrosine kinase (TK) domain (Takahasi et al, 1988), and
recently it has been shown that its putative ligands are the Glial-
cell-line Derived Neurotrophic Factor (GDNF), neurturin,
artemin, enovin and persephin (Suárez, 1998a, b; Jhiang, 2000).
The gene is expressed in a variety of neuronal cell lineages, as well
as in the kidney and enteric nervous system (Suárez, 1998a). The
activated  ret oncogene was first isolated by the transfection 
of NIH-3T3 cells with DNA from a human T cell lymphoma
(Takahashi et al, 1988). Germline point mutations of ret have been
described in patients afflicted by MEN 2A and MEN 2B
syndromes or familial medullary thyroid carcinoma (FMTC), indi-
cating an involvement of ret in the pathogenesis of these diseases
(Chappuis et al, 1996; Bounacer et al, 1997). In ‘spontaneous’ or
radiation-associated PTCs, 8 forms of the ret proto-oncogene 
activated by rearrangement have been identified and designated
RET/PTC1 to RET/PTC8 (Jhiang, 2000; Klugbauer et al, 2000).
All the activated forms of the proto-oncogene are the consequence
of specific oncogenic rearrangements fusioning the TK domain 
of  ret with the 5′ domain of different genes (Suárez, 1998b;
Klugbauer and Rabes, 1999). The RET/PTC activating rearrange-
ments of the ret proto-oncogene are with ras-activating point
mutation and trk-activating rearrangements, the most frequent
genetic alteration observed in PTCs (Suárez, 1998a, b). 
Indeed, contrasting with the high and very similar frequency
(about 60%) of activation by rearrangement observed in the thera-
peutic or accidental radiation-associated tumours (Bounacer et al,
1997), the frequency of ret activation by this mechanism in ‘spon-
taneous’ thyroid tumours varies widely between different studies:
from 2.5% to 34% (Bongarzone et al, 1989, 1993; Grieco et al,
1990; Santoro et al, 1994; Delvincourt et al, 1996; Bounacer et al,
1997). It has been postulated that this variation observed in ‘spon-
taneous’ tumours, could be the result of the different geographical
origins of populations studied, the age at tumour occurrence, or the
sensitivity of the experimental methods used to detect the
rearrangement. All the RET/PTC oncogenic forms of ret, seem to
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Heath Park, Cardiff, CF4 4XN UK.be specific of PTCs. However, the chimeric transcript of
RET/PTC1 oncogene, has also been found in one study, in radia-
tion-associated follicular adenomas (Bounacer et al, 1997). 
In the present report we studied one follicular adenoma and
PTCs obtained from members of 2 unrelated families in which we
suspected a familial predisposition to develop such conditions.
The tumours were associated in these patients with thyroiditis and
Hashimoto’s thyroiditis. In order to look for the eventual presence
of RET/PTC chimeric genes in the tumours obtained from the
different members of the families and to try to verify if the familial
predisposition for PTC could be attributed to a particular and
unique RET/PTC rearrangement (germinal?), we have studied: (1)
by RT-PCR, mRNAs prepared from paraffin-embedded tissues
obtained from tumoural, thyroiditis and normal thyroid tissue
areas and from peripheral lymphocytes of members of one of the
families; and (2) by immunohistochemistry, the eventual presence
and localization in these tissues of the ret onc protein. 
MATERIALS AND METHODS 
Patients 
Both family trees are reported in Figure 1. Clinical, pathological
and molecular findings are summarized in Table 1. 
In the first family, case 1 (53 years), case 2 (27 years) and case 3
(19 years) underwent total thyroidectomy. The histological diag-
noses were a bilateral follicular and trabecular non-encapsulated
PTC in case 1, a bilateral diffuse sclerosing variant of PTC in case
2, and a PTC with one metastatic lymph node in case 3. The
patient in case 4 (32 years) underwent a partial thyroidectomy for
a nodule, which was a follicular adenoma. 
In the second family, case 5 (67 years), case 6 (42 years) and
case 7 (41 years) underwent total thyroidectomy for a bilateral
encapsulated PTC with 3 metastatic lymph nodes in case 5, and a
bilateral encapsulated PTC in case 6. In case 7 one lobe presented
a non-encapsulated papillary microcarcinoma, and the other 3
microfollicular PTCs. 
LT was intense in cases 1, 2, 3, 4 and 7. The lymphoid infiltrate
penetrates the carcinomatous areas. 
As controls we studied 4 sporadic PTCs. 
After a 10-year follow up, no recurrence of the PTCs occurred
in any patient of family 1 or 2. 
All thyroid specimens were studied macroscopically and fixed in
neutral formalin (cases 1, 2, 3, 4) or Dubosq Brazil (cases 5, 6, 7) after
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FAMILY 1 FAMILY 2
1943
(case 1)
1924
(case 5)
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(case 4)
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(case 2)
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(case 3)
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(case 6)
1950
(case 7)
1953
Thyroid adenoma
Thyroid papillary carcinoma (woman)
Thyroid papillary carcinoma (man)
Figure 1 Genealogical trees from families 1 and 2 
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 a 48-hour immersion. All the resected material was paraffin
embedded and studied with haematoxylin and eosin safranin staining. 
RNA extraction from fixed thyroid tissue samples 
RNA isolation from paraffin-embedded tissue samples was
performed according to a previously described procedure
(Bounacer et al, 1997). Briefly, 2 20 µ m tissue sections were cut
from blocks of paraffin-embedded tissue and deparaffinized in 2
serial washes of 200 µ l of xylene in 0.5 ml tubes. After centrifuga-
tion (12 000 g for 15 min), the pellet was washed twice with
200 µ l of ethanol and dried. The pellet was resuspended in 100 µ l
of 50 mM Tris pH 8.6, 1 mM EDTA, 0.5% Tween, 80 U rRNasin
Ribonuclease inhibitor (Promega), 10 U RQ1 RNase free DNAse
(Promega) and 1 M KCl containing 0.3 mg ml–1 proteinase K
(Merck), and incubated for 3 h at 37˚C and 10 min at 95˚C. After
centrifugation (12 000 g for 15 min at 4˚C), the supernatant was
transferred to a 0.5 ml tube and precipitated at –20˚C overnight
with 1:10 volume of 3 M sodium acetate and 3 volumes of ethanol.
After centrifugation, the pellet was washed with 70% ethanol, air
dried and resuspended in 40 µ l of sterilized water. 
RNAs from peripheral blood lymphocytes were prepared using
a Su total RNA isolation kit, according to the protocol of the
manufacturer (Promega). 
RT-PCR method for detecting RET/PTC oncogenes, ret
gene expression and β -actin gene as a reporter target
for amplification 
The reverse transcription (RT) reaction was performed with 8 µ l 
of RNA extracted from paraffin-embedded tissue extracts. The 
RNA was reverse transcribed by incubation for 1 h at 37˚C in a final
volume of 40 µ l containing 1000 U MMLV reverse transcriptase
(Gibco, Brl), 1 × RT buffer (50 mM Tris-HCl pH 8.3, 75 mM Kcl, 3
mM Mg Cl2), 1 mM of each dNTP (Pharmacia), 4 mM DTT (Gibco,
Brl), 1 U rRNAsin Ribonuclease Inhibitor (Promega) and 500 ng of
Random hexamers (Pharmacia). The reaction was stopped by incuba-
tion for 5 min at 95˚C. One quarter of the cDNA (10 µ l), was used for
PCR amplification with outer primers. A second round of PCR was
done with nested primers using 1:10 of the first round PCR product. 
The PCR amplifications were performed using an automatic ther-
mocycler (Perkin-Elmer), in the presence of 2 U of Taq polymerase
(Ampli Taq, Perkin-Elmer, Cetus), 30 pmol of each sense and anti-
sense primers, 1 × reaction buffer (10 mM Tris-HCl pH 8.3, 5 mM
KCl, 0.01% gelatine), 250 µ M of each dNTP and 1.5 mM MgCl2
in a total volume of 50 µ l. For RET/PTC oncogenes and β -actin,
PCR reaction consisted of one cycle at 94˚C for 2 min followed by
40 cycles of denaturation, annealing and extension at 94˚C (30 s),
60˚C (1 min) and 72˚C (1 min) respectively. After 10 min at 72˚C
to ensure that the final extension step was complete, aliquots
(10 µ l) of the products of the reaction were analysed by electro-
phoresis through a 2% agarose gel. PCR primer sequences used
to study the RET/PTC are given in Table 2. The primers to study
β -actin were: forward: 5′ -ctcttgctctgggcctcgtc-3′ and reverse:
5′ -ctcttgctctgggcctcgtc-3′ . To study the expression in the different
tissues of the TK domain of the RET gene, the PCR reaction
consisted of 35 cycles of amplification at 95˚C for 30 s, 55˚C for
30 s, and 72˚C for 1 min and the primers were out-nested primers:
5′ -caccggatggagaggccagacaactgcagc-3′ forward and 5′ -accggc-
cttttgtccggctc-3′ reverse. 5 µ l of the reaction product were ampli-
fied in a second round PCR reaction using the in-nested primers
5′ -gagaggccagacaactgcagc-3′ forward and 5′ -ccttttgtccggctcct-
gcttccagcattg-3′ reverse. These primers correspond to exon 16, 5′
upstream and exon 17, 3′ downstream spanning a 1150 bp intron
of  ret. Precautions were taken to prevent PCR contamination.
Indeed, in each experiment RNA-negative samples, or samples
containing normal RNA prepared from normal thyroid tissue
without C cells, were run in parallel. 
Immunohistochemical study 
The immunohistochemical study was performed with a polyclonal
antithyrocalcitonin antibody (Ab) (Dako 1/50), and a ret poly-
clonal anti-TK domain Ab (C-19)G from Santa Cruz. 
The different tests were carried out with an LSAB (R)2 peroxi-
dase kit (Dako) according to a previously described procedure
(Gaulier et al, 1994) or a Ventana automated procedure. The slide
pretreatment included heating with a pressure cooker in EDTA
pH 7 and incubation in 40% formic acid (20 min). The final
working dilution for the polyclonal ret Ab was 1/200. 
Positive control was carried out by labelling ganglion cells on
human appendix sections with ret Ab. Negative control for the
immunostaining was carried out by replacing the primary Ab with
non-immune rabbit serum. 
Papillary thyroid carcinoma and RET/PTC rearrangements 1833
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Table 2 Sequences of the primers used in our RT-PCR experiments to detect RET/PCR rearrangements 
Sequence Localization 
c-ret primers 
tm1 (outer forward) 5′ -CTG TCC TCT TCT CCT TCA TC-3′ exon 11, nt 1853–1872 
retc2 (outer reverse) 5′ -TGC AGG CCC CAT ACA ATT TG-3′ exon 13, nt 2295–2314 
26 (in-nested forward) 5′ -TCC ATG GAG AAC CAG GTC TCC-3′ exon 11, nt 2026–2046 
RET/TK (in-nested reverse) 5′ -CTT TCA GCA TCT TCA CGG-3′ exon 12, nt 485–493 
H4 primers 
RET/PTC1 (outer forward) 5′ -ATT GTC ATC TCG CCG TTC-3′ H4 exon 1, nt 196–213 
PTCI (in-nested) 5′ -AGA TAG AGC TGG AGA CCT AC-3′ H4 exon 1, nt 272–291 
RIα primers 
RET/PTC2 (outer forward) 5′ -TAT CGC AGG AGA GAC TGT GAT-3′ RIα , nt 483–503 
PTC II (in-nested forward) 5′ -AGG GAG CTT TGG AGA ACT TG-3′ RIα , nt 600–619 
ELE1 primers 
PTC III (outer forward) 5′ -CAT GCC AGA GCA GAA GTC A-3′ ELE1, nt 634–652 
RET/PTC3 (in-nested forward) 5′ -AAG CAA ACC TGC CAG TGG-3′ ELE1, nt 697–714 RESULTS 
Research of RET/PTC rearrangements in tumoural and
nontumoural tissues infiltrated by lymphocytes 
RET/PTC1 transcripts were detected in all the papillary carci-
nomas of family 1, whereas all the non-tumoural tissues presenting
lymphocytic infiltration, and the adenoma from one of the
members of this family, were negative (Figure 2A). In this family,
all the samples were negative for RET/PTC2 and PTC3 (data not
shown). 
Concerning family 2, our data showed a strong band of
RET/PTC3 positivity in all the papillary carcinomas. In the non-
tumoural tissues infiltrated by lymphocytes, a band of positivity
was also observed with an intensity varying slightly between the
samples representative of the different members of the family. The
intensity of the RET/PTC2 bands in the thyroiditis samples was, in
all the cases, lower than in the tumours (Figure 3A). These
samples were negative for RET/PTC1 and PTC2 (data not shown). 
All the sporadic PTCs used as controls were negative for
RET/PTC1, PTC2 and PTC3 (data not shown). 
We also studied by RT-PCR the expression of the TK domain of
ret in the different samples of both families. Expression of the ret
TK domain is not normally detected in the thyroid gland, because
the gene is only expressed in parafollicular C cells, which consti-
tute about 1% of the normal thyroid cellular population (Suárez,
1998a). In our experiments we observed that in family 1, there was
expression of the ret TK domain in the samples corresponding to
the 3 papillary carcinomas. Surprisingly, a faint band of expression
was also observed in the non-tumoural thyroid tissues infiltrated
by lymphocytes of the patients bearing a carcinoma. The adeno-
matous tissue and its corresponding normal control were negative
(Figure 2C). In samples of family 2, ret TK expression was
detected in all carcinomatous as well as thyroiditis samples. The
bands of positivity were weaker in the latter tissues (Figure 3C).
As expected, ret TK expression was not detected in the normal
unrelated control tissues (see the figures). 
With the aim to establish whether or not the ret rearrangements
were somatic or germinal, we also studied by RT-PCR RNAs
extracted from the peripheral blood samples of 3 of the members
of family 2 (patients 5, 6 and 7) positive for RET/PTC3, as well as
genetic material prepared from a thyroid dystrophy diagnosed in
one of their cousins. The data were negative (data not shown). 
To confirm that the negative results were due neither to RNA
degradation nor to a failure of extraction, a similar length of RNA
transcript from the ubiquitously expressed β -actin gene was used
as a reported target for amplification. As shown in the figures, an
actin signal (72 bp long) was observed with a similar intensity in
all the samples studied (Figures 2, 3B, D). Moreover, to eliminate
all possibility of PCR contamination, a sample without RNA was
added to all the experiments (see the figures). 
Immunohistochemistry 
The calcitonin labelling does not show C cell hyperplasia in any of
the tissues studied (data not shown). 
The polyclonal ret Ab gave a faint diffuse cytoplasmic labelling
in cases 1, 2 and 3 in carcinomatous areas (Figure 4). In non-
carcinomatous inflammatory areas, a faint and heterogeneous,
cytoplasmic and apical labelling was observed, being noticed in
some areas and absent in others (Figure 5). 
In cases 5 and 7 (Figure 6), a strong apical labelling of the carci-
nomatous cells appeared in some areas. This apical labelling was
weaker in case 6 (data not shown). In these 3 cases, the epithelial
cells labelling of LT areas was unsteady, with cytoplasmic or
apical labelling (data not shown). 
No immunohistochemical labelling was observed in the
adenoma (case 4). 
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Figure 2 Research by RT-PCR in members of family 1 of: (A) ret
rearrangements. Lanes: a, c, and e: presence of RT/PTC 1 in the PTCs from
cases 1, 2 and 3; b, d, f and h: absence of RET/PTC in thyroiditis from cases
1, 2, 3 and 4; g and i: absence of RET/PTC in the follicular adenoma from
case 4 and in normal thyroid tissue; j: PCR reaction in the absence of genetic
material. (C) ret TK domain expression. Lanes: a, c and e: in PTCs from
cases 1, 2 and 3; b, d, f, and h: in thyroiditis from cases 1, 2, 3 and 4; g and i:
in the follicular adenoma from case 4 and in normal thyroid tissue; j: PCR
reaction in the absence of genetic material. (B, D) β -actin control of quantity
and quality of genetic material. Ethidium bromide-stained 2% agarose gels of
second round PCR products. M: molecular weight marquer ØX 174/Hae III
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Figure 3 Research by RT-PCR in members of family 2 of: (A) ret
rearrangements. Lanes: a, c and e: presence of RET/PTC 3 in the PTCs from
cases 5, 6 and 7; b, d and f: presence of RET/PTC 3 in thyroiditis from cases
5, 6 and 7; g: normal thyroid tissue; h: PCR reaction in the absence of
genetic material. (C) ret TK domain expression. Lanes: a, c and e: in PTCs
from cases 5, 6 and 7; b, d and f: in thyroiditis from cases 5, 6 and 7; g:
normal thyroid tissue; h: PCR reaction without genetic material. (B, D) β -actin
control of quantity and quality of genetic material. Ethidium bromide-stained
2% agarose gels of second PCR products. M: molecular weight marquer ØX
174/Hae III 
Figure 4 Diffuse cytoplasmic labelling in a PTC of follicular pattern (case 2),
using a polyclonal ret antibody (1/200) (magnification × 300).
Lymphoplasmacytic infiltrate in the stroma is also stained A faint and focal apical labelling was observed in one of the 4
sporadic control PTCs without RET/PTC rearrangement. All the
other control sporadic PTCs were negative. In all the patients, the
parenchyma without carcinoma and without LT was unstained
(Figure 7). 
DISCUSSION 
We looked for the eventual presence of ret proto-oncogene alter-
ations, in members of 2 families presenting thyroid tumours, in
majority of the papillary carcinoma type. Our results were
compared with data obtained by screening non-tumoural thyroid
tissue infiltrated by lymphocytes collected from the same patients,
unrelated normal thyroid tissue and 4 unrelated sporadic papillary
carcinomas. 
In our study, carried out using the RT-PCR technique, all the
PTCs presented a RET/PTC-activating rearrangement, from the
PTC1 type in family 1 and from the PTC3 type in family 2. The
follicular adenoma of one of the members of family 1 was nega-
tive. As for the non-tumoural thyroid tissues infiltrated by lympho-
cytes, the data were different in the 2 families. Whereas in family 1
all the samples were negative, in family 2 they were positive, but
weaker than in the respective carcinomatous samples. It is inter-
esting to point out that, when the degree of expression of the TK
domain of ret was studied in thyroiditis or malignant thyroid
tissues of both families, a variable ret activation was identified in
all the samples by the presence of a PCR product of the predicted
size. The exceptions were the adenoma of one of the members of
family 1 and the control normal thyroid tissues, in which ret
expression was not detected. 
In family 2, as expected because of the detection in these
samples of RET/PTC3 transcripts, we found the presence of ret
expression in thyroid tissues infiltrated by lymphocytes.
Unexpectedly in family 1 we found the presence of ret expression
in thyroid tissues infiltrated by lymphocytes, while 3 independent
experiments to detect the presence of RET/PTC chimeric cDNAs
had been negative. Moreover we did not find the presence of
tumour cells nor C cell hyperplasia in these tissues. The signal of
ret TK domain expression being very weak in the thyroiditis
samples of family 1, we can hypothesize a RET/PTC1 rearrange-
ment in a minority of ‘normal’ thyrocytes, below the threshold of
detection in our RT-PCR experiments. Another hypothesis might
be the possible presence of rare isolated tumour cells in lympho-
cytic thyroiditis undetected by histology. 
In PTC areas, the results of immunohistochemistry and RT-PCR
correlated: the neoplastic cells of the 3 RET/PTC1-positive
tumours and those of the 3 RET/PTC3-positive tumours displayed
a distinct labelling. However, this labelling was diffuse and cyto-
plasmic in family 1 and apical in family 2. The diffuse cytoplasmic
labelling type has already been reported in cases of PTC with
RET/PTC1 activation (Sugg et al, 1998). Moreover, this type of
labelling was found in PTC associated with familial adenomatous
polyposis (Cetta et al, 1998), and has also been described in occult
PTC (Viglietto et al, 1995). In our study, the faint labelling may be
related to a low expression of ret protein by the RET/PTC1 onco-
gene as previously described by Jhiang et al (1996). Different
levels of ret expression have been described with an intracyto-
plasmic or membranous localization. Recently, a membranous ret
immunolabelling was described in 20 out of 99 PTCs presenting
an overexpressed apparently wild-type ret gene, whereas a diffuse
cytoplasmic labelling was observed in tumours with RET/PTC1, 2,
3 or 4 rearrangements (Ishizaka et al, 1992; Mayr et al, 1999).
However, staining in PTC associated with a RET/PTC3 rearrange-
ment has been reported infrequently and the different ret products
have been described as localized in different cell compartments
(Ishizaka et al, 1992). 
In the LT areas, interpretation of immunohistochemical staining
is difficult because of variable results. This interpretation is also
hampered by a possible unrecognized tumour cell extension and by
the ret expression of the lymphoplasmacytic infiltrate (Nakayama
et al, 1999). With such restrictions, our findings suggest however
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Figure 5 Faint apical labelling of epithelial cells in LT area, without
carcinomatous invasion (polyclonal ret antibody 1/200, magnification × 300,
case 2) 
Figure 6 Dense apical staining in a PTC of follicular pattern (polyclonal ret
antibody 1/200, magnification × 400, case 7) 
Figure 7 Dense apical staining in a PTC of follicular pattern. Several
unlabelled non-tumoural follicles are shown (polyclonal ret antibody 1/200,
magnification × 400, case 5) an immunohistochemical ret protein expression in a few non-
carcinomatous follicular epithelial cells in LT areas in both fami-
lies 1 and 2, without clear-cut correlation between ret
rearrangement and immunohistochemical ret protein expression.
These data could be explained by a low abnormal expression of
the wild-type ret gene as suggested by recent data of Bunone et al
(2000) or, alternatively, by the presence of unknown forms of ret
rearrangements. The expression of ret protein in the LT areas was
shown in a recent publication (Sugg et al, 1998). Indeed, among 3
non-tumoural tissues with ret rearrangement studied by these
authors, one case expressed a ret immunoreactivity in atypical
epithelial cells associated with thyroiditis. 
Our present data agree with results of previous publications
(Suárez, 1998a, b) showing that ret activation in ‘spontaneous’
tumours is confined to papillary carcinomas. However, the pres-
ence of the same type of RET/PTC rearrangement in the tumoural
genetic material of family 1 and tumoural and thyroiditis genetic
material of members of family 2, raises several questions: whether
or not (1) the mutation is germinal; (2) the members of these fami-
lies are carriers of a common ‘fragile’ region in one (or both) of
the genes participating at the formation of the RET/PTC chimeric
genes, which may be the preferential target of different unknown
genotoxic agents giving rise to the rearrangement or (3) the so-
called  ‘spontaneous’ tumours of these patients are the conse-
quence of inadvertent exposure to lower doses of radiation or other
genotoxic agents. 
Our data showing the absence of ret rearrangements in blood
samples of 3 of the members of family 2 presenting a RET/PTC3
chimeric gene in their tumours, as well as in the genetic material
prepared from a thyroid dystrophy diagnosed in one of their
cousins, suggest that the mutation is somatic. 
In regard to the second question, we are unable to verify it
because we do not have enough biological material to study by
XL-PCR the genomic sequences where the break-points are gener-
ally located in the different RET/PTC rearrangements known until
present (Grieco et al, 1990; Bongarzone et al, 1993; Santoro et al,
1994; Fugazzola et al, 1996; Bounacer et al, 1997; Suárez, 1998b).
Finally, concerning the third question, there was no evidence in the
clinical history of our patients of a possible low-dose irradiation
and/or a chemical agent aggression. If the latter possibility cannot
be completely discarded, the second hypothesis remains the most
plausible one. Activating rearrangements of ret and other genes
with TK activity (i.e. trk and met) are the consequence mainly of
radiation and more rarely of chemical mutagens or perhaps other
unknown genotoxic agents (Michelin et al, 1993; Sarasin et al,
1999). We can assume that the action of one of these genotoxic
agents acting on a common ‘fragile’ site carried by our patients in
one (or both) of the genes constituting the RET/PTC oncogene,
may be at the origin of the rearrangements observed. 
Our study is the first to demonstrate the presence of the same
RET/PTC gene and overexpression of the tyrosine kinase domain
of ret, in the papillary carcinomas of members of 2 unrelated fami-
lies: in one case PTC1 and in the other PTC3. Moreover, our
present and previous data (Bounacer et al, 1997) as well as data
from different laboratories (Viglietto et al, 1995; Santoro et al,
1996; Wirtschafter et al, 1997; Cho et al, 1999) confirm that
RET/PTC oncogenic activation is an early event of thyroid epithe-
lial tumorigenesis. 
In conclusion, altogether our data suggest that: (1) we are in the
presence of familial PTCs in which RET/PTC may play a role of
‘marker’. However, this marker seems to be particular to each
family rather than a common one; (2) RET/PTC rearrangements
are early events in PTC development, being already present in the
‘normal’ thyrocytes of the regions infiltrated by lymphocytes; and
(3) these mutations may be the consequence of, until now,
unknown genetic and/or microenvironmental factors, at least in
our patients. Moreover, our results agree with those of Okayasu 
et al (1995) suggesting that lymphocytic thyroiditis is not only
frequently associated to papillary carcinoma but is perhaps a
predisposing factor for tumour development, as suggested by the
presence of the same RET/PTC rearrangement in both tumoural
and inflammatory tissues in the same patient. 
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